MARIPOSA Study Shows Benefit of Amivantamab/Lazertinib in EGFR+ NSCLC
Nicolas Girard, MD, discusses data from the phase 3 MARIPOSA trial of amivantamab-vmjw plus lazertinib for patients with advanced non–small cell lung cancer harboring classical EGFR sensitizing mutations.
Maximizing the Clinical Benefit of Crizitonib in NSCLC
Nicolas Girard, MD, discusses how to maximize the clinical benefit of crizitonib (Xalkori) in non-small cell lung cancer (NSCLC).